Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma

Classical Hodgkin lymphoma is biologically different than other lymphomas. The cancer cells only occupy a small amount of the lymph node and evade the immune system by amplification of PD-L1 and PD-L2. Therefore, checkpoint inhibitors are a logical treatment option for Hodgkin lymphoma patients to u...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Adam Yuh, Schnitter, Joseph Michael, Gordon, Leo I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882667/
https://www.ncbi.nlm.nih.gov/pubmed/35237537
http://dx.doi.org/10.2147/ITT.S284988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882667/
https://www.ncbi.nlm.nih.gov/pubmed/35237537
http://dx.doi.org/10.2147/ITT.S284988

Ejemplares similares